Researcher in lab

Find clinical trials

Our clinical trial portfolio is one of the largest in the country. We have more than 700 clinical trials open across 30 clinical units.

Find Melbourne Sexual Health Centre research studies and clinical trials
Clear filter
627 clinical trials found
Clinical trials

COSTAR

A Randomized, Open Label Phase 2/3 Study Comparing Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in With Advanced Nonsmall Cell Lung Cancer who have Progressed on Prior Anti-PD(L)1 Therapy and Chemotherapy (NCT04655976)

No longer recruiting

CP-AU-007-01

A Phase 1/2, First-in-Human, Open Label, Dose Escalation and Expansion Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Ra Binding, in Patients with Unresectable Locally Advanced or Metastatic Cancer (NCT05267626)

Currently recruiting

CP-MVC-101-01

A Phase 1/2, First-in-Human, Open-Label, Dose-Escalation Study of TAK-186 (Also Known as MVC-101), An EGFR x CD3 COnditional Bispecific Redirected Activation (COBRA) Protein in Patients With Unresectable Locally Advanced or Metastatic Cancer (NCT04844073)

Currently recruiting

CPHE885B12201

A Phase 2 Study of PHE885, a BCMA-directed CAR-T Cell Therapy for Patients with Relapsed and Refractory Multiple Myeloma (NCT05172596)

Currently recruiting

CROSSING

A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Phase III Efficacy and Safety Study of Tezepelumab in Patients with Eosinophilic Esophagitis (CROSSING) (NCT05583227)

Currently recruiting

CRSP-ONC-006

A Phase 1/2, Open-Label, Multicenter, Dose Escalation and Cohort Expansion Study of the Safety and Efficacy of Anti-CD19 Allogeneic CRISPR-Cas9–Engineered T Cells (CTX112) in Subjects With Relapsed or Refractory B Cell Malignancies (NCT05643742)

Currently recruiting

CRSP-ONC-LTF

A Long-term Follow-up Study of Subjects With Malignancies Treated With CRISPR CAR T Cellular Therapies (NCT06208878)

This study will evaluate the long-term safety and efficacy of CRISPR CAR T cellular therapies.
Coming soon

CRVOMed Study

A Double-Blind, Placebo-Controlled, Proof-of-Concept Clinical Study of the P38 Alpha Kinase Inhibitor Neflamapimod on Recovery after Ischemic Stroke (NCT06987643)

Currently recruiting

CS2009

A Phase I, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activities of CS2009, a tri-specific antibody targeting PD-1/VEGFA/CTLA-4, in Participants with Advanced Solid Tumors (NCT06741644)

Currently recruiting

CSL TAP

A Prospective, Multicentre, Randomized, Double-Blind, Placebo-Controlled, Large Simple Trial Evaluating the Use of BE1116 (4-Factor Prothrombin Complex Concentrate [Kcentra® / Beriplex® ]) to Improve Survival in Patients with Traumatic Injury and Acute Major Bleeding (NCT05568888)

No longer recruiting

CSL222_3005

Phase 3b, Open-label, Multicenter, Single-dose Study Investigating Efficacy and Safety of CSL222 [Etranacogene Dezaparvovec] Gene Therapy Administered to Adult Subjects with Severe or Moderately Severe Hemophilia B with Detectable Pretreatment AAV5 Neutralizing Antibodies (NCT06003387)

Currently recruiting

CSL312-3002

An Open label study to evaluate the long term safety and efficacy of CSL312 (garadacimab) in the prophylactic treatment of hereditary angioedema (NCT04739059)

No longer recruiting

CT LEFT MAIN

The role of CT Angiography as a suitable alternative to Invasive Coronary Angiography in detecting Left Main Restenosis (Trial Not Registered)

No longer recruiting

CVAY736I12301 - VAYHIT1

A phase 3, randomized, double-blind study of ianalumab (VAY736) versus placebo in addition to first-line corticosteroids in primary immune thrombocytopenia (VAYHIT1) (NCT05653349)

Currently recruiting

CVAY736J12101

A phase Ib, multi-center, open-label dose escalation and expansion platform study of VAY736 as single agent and in combination with select antineoplastic agents in patients with non-Hodgkin Lymphoma (NHL) (NCT04903197)

No longer recruiting

CVAY736O12301 - VAYHIA

A phase 3, randomized, double-blind, study to assess efficacy and safety of ianalumab (VAY736) versus placebo in warm autoimmune hemolytic anemia (wAIHA) patients who failed at least one line of treatment (VAYHIA) (NCT05648968)

Currently recruiting

CVAY736Q12201

A phase 2 study to evaluate the efficacy and safety of ianalumab in patients with primary immune thrombocytopenia (ITP) previously treated with at least two lines of therapy (NCT05885555)

Currently recruiting

CYPRESS

A Phase 3, Multi-center, Randomized Withdrawal and Long-Term Extension Study of Ampreloxetine for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension in Participants with Multiple System Atrophy (NCT05696717)

No longer recruiting

CYTB323A12101

Phase I/II, open label, multicenter study of YTB323 in adult patients with CLL/SLL, 3L+ DLBCL, ALL and 1L HR LBCL (NCT03960840)

Currently recruiting

CYTB323L12201

A Phase 2, randomized, open-label, controlled study to evaluate the efficacy and safety of rapcabtagene autoleucel versus comparator in participants with severe refractory idiopathic inflammatory myopathies (NCT06665256)

The CYTB323L12201 study is designed to evaluate the safety and efficacy of rapcabtagene autoleucel (CAR-T) compared to standard of care treatment in participants with idiopathic inflammatory myopathies (IIM). Participants will be randomised into either a CAR-T infusion or a comparator option. After the end of study participants who received the CAR-T infusion will enter a long-term follow-up period lasting up to 15 years.

Coming soon
8 9 10 11 12